INMED PHARMACEUTICALS ANNOUNCES THE CLOSING OF C$14.95 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF UNDERWRITER’S OVER-ALLOTMENT OPTION

June 21, 2018
InMed Pharmaceuticals Inc.

Vancouver, BC, Canada – June 21, 2018 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the “bought deal” financing (the … Continue reading INMED PHARMACEUTICALS ANNOUNCES THE CLOSING OF C$14.95 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF UNDERWRITER’S OVER-ALLOTMENT OPTION

Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

Aequus Pharmaceuticals Inc.

Key Highlights Aequus and Corium have expanded their relationship to include Aequus’ long-acting, transdermal patch for nausea and vomiting in pregnancy, AQS1303; Corium will utilize Corplex™, its industry leading, proprietary transdermal technology, to further advance AQS1303 for clinical testing; Corium will perform certain formulation work at no cost to Aequus in exchange for exclusive manufacturing … Continue reading Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

Precision NanoSystems raises US$6 Million to Accelerate Product Innovation and Global Expansion

June 20, 2018
Precision NanoSystems Inc.

VANCOUVER, June 7, 2018 /PRNewswire/ – Precision NanoSystems (PNI) today announced that it has closed a US$6MSeries B investment. The funds will be used to expand PNI’s products and services globally and to provide a clinical manufacturing solution targeted at organizations developing precision and personalized nanomedicines. The financing round included participation from existing investors 5AM Ventures, Telegraph Hill Partners, and Rising Tide … Continue reading Precision NanoSystems raises US$6 Million to Accelerate Product Innovation and Global Expansion

More Precise RA Patient Care; New data on the 14-3-3 blood test to help optimize treat-to-target strategies

June 18, 2018
Augurex Life Sciences Corp.

More Precise RA Patient Care; New data on the 14-3-3η blood test to help optimize treat-to-target strategies At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. … Continue reading More Precise RA Patient Care; New data on the 14-3-3 blood test to help optimize treat-to-target strategies

Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System

Aequus Pharmaceuticals Inc.

VANCOUVER, BC. June 18, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy System (“Zepto”), a precision pulse capsulotomy device, have been successfully completed this week by Dr. Ike Ahmed at the Kensington Eye Institute in … Continue reading Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System

Arbutus Biopharma to Present at First Annual Roivant Pipeline Day

Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., June 18, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. A live webcast will be available via the … Continue reading Arbutus Biopharma to Present at First Annual Roivant Pipeline Day

First Four Cataract Procedures Completed Using Zepto Capsulotomy System

Aequus Pharmaceutical

VANCOUVER, BC. June 18, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy System (“Zepto”), a precision pulse capsulotomy device, have been successfully completed this week by Dr. Ike Ahmed at the Kensington Eye Institute in … Continue reading First Four Cataract Procedures Completed Using Zepto Capsulotomy System

Dr. Dermot Kelleher has been appointed as Vice-President, Health, for UBC

UBC

A message from Professor Santa J. Ono, President and Vice-Chancellor I am pleased to announce that Dr. Dermot Kelleher has been appointed as Vice-President, Health, for UBC. Dr. Kelleher is currently Dean of the Faculty of Medicine. He will take on the role of Vice-President, Health, in addition to his responsibilities as Dean, from July 1, 2018 … Continue reading Dr. Dermot Kelleher has been appointed as Vice-President, Health, for UBC

Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer

June 13, 2018
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., June 07, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June 11, 2018.  Mr. Hastings will assume the CFO role from Koert VandenEnden, Arbutus’ interim Chief Financial Officer. … Continue reading Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer

Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS

June 11, 2018
Aquinox Pharmaceuticals

– Trial Will Enroll Approximately 100 Male Subjects in the US and Canada – VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today announced initiation of dosing in ProShip, a Phase … Continue reading Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS